1ORNBV Orion Corporation

ORION CORPORATION MANAGERS’ TRANSACTIONS 16 NOVEMBER 2023 at 10.15 EET         

Orion Corporation: Managers’ transactions – Agendum Oy

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Agendum OyPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Mikael SilvennoinenPosition: Member of the BoardIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 43741/5/6

____________________________________________Transaction date: 2023-11-15Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009014377Nature of transaction: ACQUISITION

Transaction details(1): Volume: 56 Unit price: 37.6 EUR (2): Volume: 100 Unit price: 37.6 EUR (3): Volume: 563 Unit price: 37.6 EUR

Aggregated transactions (3): Volume: 719 Volume weighted average price: 37.6 EUR____________________________________________Transaction date: 2023-11-15Venue: CEUXInstrument type: SHAREISIN: FI0009014377Nature of transaction: ACQUISITION

Transaction details(1): Volume: 73 Unit price: 37.6 EUR (2): Volume: 586 Unit price: 37.6 EUR (3): Volume: 100 Unit price: 37.6 EUR (4): Volume: 400 Unit price: 37.6 EUR (5): Volume: 32 Unit price: 37.6 EUR

Aggregated transactions (5): Volume: 1191 Volume weighted average price: 37.6 EUR

Orion Corporation

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024